Advaccine Biopharma Suzhou announced a $108 million agreement to acquire Greater China rights to a DNA vaccine for COVID-19 from Inovio of Pennsylvania . As part of the deal, Advaccine will out-license its plasmid manufacturing process to Innovio for use with INO-4800, the COVID vaccine, and its other candidates. Advaccine is already collaborating with Inovio in a China Phase II trial of INO-4800 that has enrolled 640 subjects. The endpoints of the test are safety and immunogenicity in a China population. More details.... Stock Symbol: (NSDQ: INO) Share this with colleagues: // //